DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
48 hedge funds and large institutions have $2.16M invested in DMK Pharmaceuticals Corporation Common Stock in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 6 closing their positions.
2,740% more call options, than puts
Call options by funds: $142K | Put options by funds: $5K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
12% more funds holding
Funds holding: 43 → 48 (+5)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
15% less capital invested
Capital invested by funds: $2.55M → $2.16M (-$395K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$15.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.4K |
| 3 |
VF
Virtu Financial
New York
|
+$12.1K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$7.18K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.5K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$12K |
| 5 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
-$4K |
DMK Hedge Fund Activity: Q4 2022 in Review
48 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2022, worth a combined $2.16M — down 15% from $2.55M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new DMK positions and 6 closed out — a net gain of 5 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $15.8K. The largest seller was Susquehanna International Group, cutting an estimated $28.2K.
- 48 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2022, up from 43 in Q3 2022.
- Funds reported $2.16M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2022, down 15% quarter-over-quarter.
- 11 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2022 and 6 closed out, a net change of +5 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2022 was Jane Street, an estimated $15.8K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2022 was Susquehanna International Group, an estimated $28.2K sold.
Based on aggregated 13F filings for Q4 2022.